GHRP-6 is a synthetic growth hormone secretagogue. Research has shown that it elicits a dose-related release of growth hormone (GH) in vivo and in vitro. GHRP-6 has also been found to enhance stage 2 sleep and cortisol release in healthy men.
Results from a clinical trial show that GHRP-6 is more effective than GH-releasing hormone (GHRH) in increasing GH secretion in patients with hypothyroidism.
Furthermore, in an animal study, GHRP-6 treatment prevented the failure of cardiac function.
Growth hormone releasing peptide-6 is a synthetic hexapeptide that stimulates the secretion of GH. Just like GHRP-2, GHRP-6 is a ghrelin receptor agonist. Ghrelin is a hormone that regulates appetite, protects cardiovascular health, and stimulates GH secretion from the pituitary.
GHRP-6 was the first ever synthetic peptide that elicited a dose-related release in GH in vivo and in vitro. It was only after this peptide’s success that a heptapeptide, GHRP-1, and two other hexapeptides, GHRP-2 and Hexarelin, were synthesized and addressed by clinical studies.
Various clinical studies have been conducted on GHRP-6. These studies have shown that GHRP-6 elicits GH release in normal men as well as those with hypothyroidism. Furthermore, GHRP-6 has been shown to enhance second-wave sleep and cortisol release in healthy men.
In animal and cell-based studies, GHRP-6 has been shown to enhance learning and memory, protect brain tissue during acute stroke, and expedite wound healing. The peptide has also been found to prevent failure of cardiac function and alleviate depression in animal models.